Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

NCT02479087 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Plasma-derived FVIII/VWF concentrate

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Collaborators

[object Object]